MP46-17 PATIENT-REPORTED URINARY CONTINENCE FOLLOWING SALVAGE WHOLE GLAND PROSTATE CRYOABLATION: OUTCOMES AT THE 1-YEAR POST-SALVAGE INTERVAL

INTRODUCTION AND OBJECTIVE: Cryoablation (CA), high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and vascular targeted photodynamic therapy (VTP) have been evaluated as novel strategies for selected patients with prostate cancer (PCa). We aim to determine the current status of literature regarding the clinical outcomes among these minimally invasive therapies. METHODS: A systematic search of PubMed, EMBASE, and the Cochrane Library for all English literature published from January 2001 to December 2019 was conducted to identify studies evaluating outcomes of CA, HIFU, IRE or VTP on PCa. Proportionality with 95% con fi dence intervals (CIs) were performed using STATA version 14.0. RESULTS: 56 studies consisting of 7383 participants were found to report data of interest and ful fi lled the inclusion criteria in the fi nal meta-analysis. The pooled proportions of positive biopsy after procedure were 20.0% (95% CI 12.3%-27.6%), 24.3% (95% CI 18.0%-30.6%), 24.2% (95% CI 17.7%-30.7%), and 36.2% (95% CI 28.6%-43.8%) in CA, HIFU, IRE and VTP respectively. The pooled proportions of BRFS were 75.7% (95% CI 67.3%-84.2%) for CA and 74.4% (95% CI 65.2%-83.7%) for HIFU. The pooled proportions of CSS were 96.1% (95% CI 91.6%- 100.6%), 98.2% (95% CI 96.7%-99.7%), and 97.9% (95% CI 93.9%- 102.0%) for CA, HIFU, and IRE, respectively. The pooled proportions of OS were 92.8% (86.4%-99.2%) for CA and 85.2% (78.4%-92.0%) for HIFU. The pooled proportions of FFS were 64.7% (14.6%-114.7%), 90.4% (82.6%-98.1%), and 76.7% (68.0%-85.4%) for CA, IRE and VTP respectively. The pooled proportions of MFS were 92.8% (95% CI 92.8%-98.0%) for HIFU and 99.1% (95% CI 97.6%-100.6%) for IRE. CONCLUSIONS: This meta-analysis shows that CA, HIFU, IRE, and VTP are promising therapies for PCa patients with similar clinical outcomes. However, further lager, well-designed RCTs are required to con fi rm this assertion.